GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Somaxon Pharmaceuticals, Inc. (SOMX) [hlAlert]

Rating:
Accumulate
SOMX
down 79.16 %

Somaxon Pharmaceuticals, Inc. (SOMX) rated Accumulate with price target $3.40 by Global Hunter Securities

Posted on: Wednesday,  Jul 20, 2011  8:25 AM ET by Global Hunter Securities

Global Hunter Securities rated Accumulate Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) on 07/20/2011, when the stock price was $14.40.
Since then, Somaxon Pharmaceuticals, Inc. has lost 79.17% as of 03/06/2015's recent price of $3.00.
If you would have followed this Global Hunter Securities's recommendation on SOMX, you would have lost 79.16% of your investment in 1325 days.

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR, is in Phase III clinical trials for the treatment of insomnia

Global Hunter Securities uses a disciplined quantitative and qualitative approach, our analysts are focused on covering small-cap companies with unique value and above average growth, primarily in the following sectors: Consumer, Energy, Healthcare, Industrial, Services and Technology. Additionally, Global Hunter Securities has analysts specifically focused on Special Situations and International opportunities. Global Hunter Securities' analysts maintain strong relationships and ongoing dialogue with management teams and industry professionals to ensure propitious access to information.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/20/2011 8:25 AM Buy
None
14.40 27.20
as of 12/30/2011
1 Week down  -21.05 %
1 Month down  -36.61 %
3 Months down  -48.27 %
1 YTD down  -75.00 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy